ObsEva SA (NASDAQ:OBSV)‘s stock had its “outperform” rating restated by equities research analysts at Leerink Swann in a research report issued on Wednesday. They presently have a $18.00 price objective on the stock. Leerink Swann’s price objective would suggest a potential upside of 134.22% from the stock’s previous close.

Other research analysts have also issued reports about the stock. HC Wainwright set a $27.00 target price on shares of ObsEva SA and gave the company a “buy” rating in a report on Wednesday. Zacks Investment Research upgraded shares of ObsEva SA from a “sell” rating to a “hold” rating in a report on Wednesday, July 19th. Finally, Credit Suisse Group restated an “outperform” rating and issued a $27.00 target price on shares of ObsEva SA in a report on Tuesday, April 18th. One equities research analyst has rated the stock with a hold rating and four have issued a buy rating to the stock. The stock currently has a consensus rating of “Buy” and a consensus target price of $23.25.

ObsEva SA (NASDAQ:OBSV) opened at 6.7099 on Wednesday. ObsEva SA has a 52 week low of $5.00 and a 52 week high of $14.70. The stock’s market capitalization is $178.64 million. The firm’s 50-day moving average is $7.89 and its 200-day moving average is $9.12.

ObsEva SA (NASDAQ:OBSV) last released its earnings results on Tuesday, August 15th. The company reported ($0.61) earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of ($0.48) by $0.13. During the same quarter in the prior year, the firm posted ($0.30) EPS. On average, equities research analysts predict that ObsEva SA will post ($2.04) EPS for the current fiscal year.

ILLEGAL ACTIVITY WARNING: “ObsEva SA’s (OBSV) “Outperform” Rating Reaffirmed at Leerink Swann” was posted by American Banking News and is the sole property of of American Banking News. If you are viewing this news story on another domain, it was copied illegally and reposted in violation of US and international copyright legislation. The original version of this news story can be viewed at https://www.americanbankingnews.com/2017/08/16/obseva-sas-obsv-outperform-rating-reaffirmed-at-leerink-swann.html.

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in OBSV. Baker Avenue Asset Management LP purchased a new position in ObsEva SA during the first quarter worth about $104,000. Paloma Partners Management Co purchased a new position in ObsEva SA during the first quarter worth about $131,000. Sphera Funds Management LTD. raised its position in ObsEva SA by 9.7% in the second quarter. Sphera Funds Management LTD. now owns 231,497 shares of the company’s stock worth $1,979,000 after buying an additional 20,411 shares during the period. Iguana Healthcare Management LLC purchased a new position in ObsEva SA during the first quarter worth about $260,000. Finally, Spark Investment Management LLC purchased a new position in ObsEva SA during the first quarter worth about $518,000. Institutional investors own 49.11% of the company’s stock.

ObsEva SA Company Profile

Obseva SA is a Switzerland-based company active in the pharmaceutical and medical research sector. The Company develops oral compounds to treat women’s reproductive health conditions from conception to birth. Its pipeline includes three product candidates: OBE2109 is an oral gonadotropin-releasing hormone (GnRH) receptor antagonist that binds to and blocks the endogenous GnRH from activating its pituitary receptors, which reduces estrogen production by the ovaries and leads to amenorrhea.

Receive News & Ratings for ObsEva SA Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ObsEva SA and related companies with MarketBeat.com's FREE daily email newsletter.